Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy
Trial details
- Registry ID
- NCT01265433
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality TherapyNCT01265433 | Sellas Life Sciences Group | Phase 2 | Completed | 2016-11-30Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |